$URGN News

Why UroGen Pharma (URGN) Is Getting Fresh Attention Now

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

UroGen Pharma: An Emerging GARP Stock

UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

Urogen Pharma: Upside After Bladder Cancer Launch

UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

UroGen (URGN) Q2 2026 Earnings Call Transcript

UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus

Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed